Abu Dhabi has become the first in the world to deliver Itvisma, a one-time gene therapy specifically designed to target the underlying genetic cause of spinal muscular atrophy (SMA) in patients aged two years and above.
Sheikh Khalifa Medical City (SKMC) has successfully administered this groundbreaking gene therapy, developed by Novartis, under the supervision of the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate.
The therapy had been previously approved by the UAE on November 25, positioning it among the first countries globally, after the USA, to endorse the pioneering treatment.
Designed for simplicity long-term impact, Itvisma (onasemnogene abeparvovec) replaces the missing SMN1 gene to improve motor function, reducing the need for continuous treatments required by other therapies.
Dr. Noura Khamis Al Ghaithi, Under-Secretary of DoH, stated that “this milestone reflects Abu Dhabi’s commitment to delivering world class care and strengthening its position as a global leader in healthcare driven by genomics and precision medicine."
UAE will remain advocates of peace, not war: Gargash
UAE sends three more aid convoys to Gaza under 'Operation Chivalrous Knight 3'
Dubai Health attracts 43,263 blood donors for ‘My Blood, for My Country’ campaign
UAE launches federal body for AI and data in push for 'government of future'
'Dubai Mallathon' enters second edition, transforming malls into fitness hubs
UAE denies media reports alleging transfer of funds to Iran
UAE, Mozambique Presidents explore stronger economic and energy ties
UAE expresses solidarity with India over military plane crash
